ABBV vs SBUX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Starbucks Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Starbucks Corporation · Consumer Cyclical
$96.67
+12.3% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
SBUX has more upside to fair value
(+12.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
SBUX |
| Current Price |
$261.70 |
$96.67 |
| Fair Value Estimate |
$259.04 |
$108.52 |
| Upside to Fair Value |
-1.0%
|
+12.3%
|
| Market Cap |
$462.4B |
$110.2B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
22.0x
|
| Price / Sales |
7.2x
|
2.9x
|
| Price / FCF |
23.6x
|
30.4x
|
| Revenue Growth YoY |
+10.2%
|
-1.4%
|
| Gross Margin |
71.5%
|
31.7%
|
| Operating Margin |
29.3%
|
9.4%
|
| Return on Equity |
-136.5%
|
-24.3%
|
| Dividend Yield |
2.61% |
2.57% |
| FCF Yield |
4.25%
|
3.29%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Starbucks is the world's largest specialty coffee retailer, operating company-owned and licensed coffeehouses across North America, International, and Channel Development segments, with a brand that has historically supported premium pricing and global scale. The business quality is currently strained: revenue declined 1.4% year over year in the most recent quarter, TTM operating margin is 9.4%, …
Accumulation Zones
| Metric |
ABBV |
SBUX |
| Zone Low |
$194.28 |
$81.39 |
| Zone High |
$220.18 |
$92.24 |
| In Buy Zone? |
No
|
No
|